Allen & Overy has advised Exscientia on the matter.The collaboration will leverage Exscientia’s AI-driven drug discovery platform to accelerate the discovery of multiple small molecule therapeutic…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
